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The year 2008 will see the continued expansion of
Current Oncology, Canada’s only multidisciplinary
journal devoted to cancer. In that spirit, the supple-
ment “Going Beyond Efficacy,” edited by Dr. Sunil
Verma, is being published together with this first issue
of main journal. Dr. Verma asked leaders from across
the country to focus on some serious issues being faced
by cancer patients and their health care providers. The
result is an eclectic mix of topics, including manage-
ment of nausea and vomiting, neutropenia and ane-
mia, thromboembolism, and iatrogenic osteopenia; use
of bisphosphonates and concerns regarding bisphos-
phonate-related osteonecrosis; and approaches to bone
metastasis and palliation. The supplement is not
“bagged” with the current issue, but will be published
simultaneously online at the Current Oncology Web
site (www.current-oncology.com). I am also very
pleased to add that Dr. Verma has accepted an invita-
tion the join the editorial board of the journal, co-ed-
iting the Medical Oncology section, and that
Dr. Raymond Nagle has also agreed to join us and to
edit a new section on Oncologic Pathology. Also join-
ing us, I am very pleased to report, are Drs. Torgny
Stigbrand (Biomarkers in Oncology) from Umeå,
Sweden, Herbert Nieburgs (Oncologic History) from
Worcester, Massachusetts, and Victor Ling (Transla-
tional Research) from Vancouver, British Columbia.
In the issue now in your hands, I am delighted to
include an Updates and Developments in Oncology
guest editorial by Drs. Serge Hardy and Michel
Tremblay, discussing the “changing” role of protein
tyrosine phosphatases. In addition, I note that
Dr. Tremblay has graciously accepted an invitation
to become involved on our editorial board, which has
continued to increase in breadth and calibre through-
out 2007.
Drs. Stephen Sagar and Raimond Wong have
written the first of a two-part series on Chinese medi-
cine and biomodulation in cancer patients, the sec-
ond part of which is scheduled for the second issue
of 2008. Our guidelines series includes recommen-
dations on supportive care of neutropenia by Dr. Tom
Kouroukis and colleagues (a topic therefore deliber-
ately not covered in “Going Beyond Efficacy”) and
cardiac management during adjuvant trastuzumab
therapy from the Canadian Trastuzumab Working
Group. Case report topics include radiation recall
dermatitis and (illegal) drug-induced “crack lung and
heart.” Dr. Nancy Levesque and colleagues discuss
the use of high-dose interferon alfa-2b in melanoma,
and writer Maya Chaddah reports on the effective—
and expanding—role of the Ontario Cancer Research
Ethics Board.
In regard to future articles, I urge all authors con-
sidering online submission to carefully review the
changing requirements for such submissions. Modi-
fications have been made to reflect the needs of our
indexing agencies and the recent policy changes con-
cerning conflict of interest, informed consent, and
human and animal rights published last year by the
International Committee of Medical Journal Editors.
The stated aim of Current Oncology is that it re-
main complimentary for our readership, a goal that
will likely continue for the foreseeable future. The
costs of publication are, in large part, borne by adver-
tising revenues and unrestricted educational grants,
mainly from the pharmaceutical industry. I have never
felt that this practice has caused a conflict of interest,
given the high calibre of our editorial writers and the
total acceptance of this position by our colleagues in
industry. In the present issue, we are embarking on a
new concept with the appearance of specific informa-
tion updates again sponsored by unrestricted grants
and written by experts in their respective fields, at the
editorial board’s specific invitation. We see these “up-
dates” as a fast track to publication, but one nonethe-
less subject to independent peer review. Our thanks
to Drs. Sunil Verma and Anil Joy for stepping up and
testing out this concept for us.
Lastly, a happy and productive 2008 to all of you
from all of us at Current Oncology, Canada’s multi-
disciplinary cancer journal, as we enter our 15th year
of publication and approach our 300th published
manuscript.
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